Figure 5.

Combined OCA and IDN-6556 treatment combats liver fibrosis. CCl₄-injured mice were enrolled to test the anti-fibrotic effect of co-administration of OCA and IDN-6556. (A) Serum ALT and AST levels. (B)–(F) Histological analysis of liver sections. H&E staining (B), Masson staining (C), Sirius Red staining (D), immunohistochemistry of α-SMA (E) and TUNEL staining (F). (G) Expression profiling of fibrosis-related genes. (H) Caspase activities of liver homogenate. Serum total BAs level (I) and profiles (J). Results are mean ± SD (n = 5), ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^#P < 0.05, ^##P < 0.01, ^###P < 0.001, ^$P < 0.05.